We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
International Flavors' (IFF) Q4 Earnings & Sales Beat Estimates
Read MoreHide Full Article
International Flavors & Fragrances Inc. (IFF - Free Report) reported adjusted earnings of $1.10 per share in fourth-quarter 2021, beating the Zacks Consensus Estimate of $1.04. The bottom line declined 17% from the year-ago quarter’s levels.
Including one-time items, the company reported earnings per share (EPS) of 35 cents compared with the prior-year quarter’s 57 cents.
International Flavors’ net sales came in at $3,031 million in the December-end quarter, surging 139% year over year. This was driven by the additional sales related to the merger with DuPont de Nemours, Inc.’s (DD - Free Report) Nutrition & Biosciences (N&B) business. The top line surpassed the Zacks Consensus Estimate of $2,960 million. During the October - December quarter, currency-neutral sales were up 10%, aided by a double-digit increase in Health & Biosciences and high-single-digit growth in Nourish, Pharma Solutions & Scent.
Operational Highlights
During the reported quarter, International Flavors’ adjusted cost of goods sold was significantly up 170% year over year to $2,044 million. Adjusted gross profit climbed 92% year over year to $987 million. Adjusted gross margin came in at 32.6% compared with 40.5% in the year-ago quarter.
Research and development expenses flared up 64% year over year to $166 million. Adjusted selling and administrative expenses shot up 92% year on year to $403 million during the fourth quarter. Adjusted operating EBITDA came in at $529 million, up 123% from the prior-year quarter’s $237 million due to the incremental profit related to the merger with N&B. Adjusted operating EBITDA margin was 17.4% compared with the year-earlier quarter’s 18.7%.
International Flavors & Fragrances Inc. Price and Consensus
Revenues in the Nourish segment soared 128% year over year to $1,626 million during the December-end quarter. Adjusted operating EBITDA was $251 million, reflecting year-over-year growth of 88.7%.
Revenues generated in the Health & Bioscience segment came in at $646 million compared with the year-earlier quarter’s $35 million. Adjusted operating EBITDA was $156 million in the quarter compared with $11 million in the prior-year quarter.
Scent segment revenues came in at $555 million compared with the year-ago quarter’s $523 million. Adjusted operating EBITDA declined 5.4% year over year to $88 million.
Revenues in Pharma Solutions were $204 million in the fourth quarter. Adjusted operating EBITDA was $34 million.
Financial Position
International Flavors had cash and cash equivalents of $715 million at the end of 2021, up from the $657 million witnessed at the end of 2020. Long-term debt increased to $10.8 billion in 2021, from $3.8 billion in 2020.
International Flavors generated $1,437 million of cash from operating activities in 2021, compared with the prior-year’s $714 million. Capital invested in purchasing property, plant and equipment totaled $393 million in 2021 compared with $192 million in 2020. Dividend paid summed $667 million in 2021.
2021 Performance
International Flavors reported an adjusted EPS of $5.63 in 2021 compared with $5.70 reported in the prior year. Earnings beat the Zacks Consensus Estimate of $5.60. Including one-time items, the bottom line came in at $1.10, down 65.7% from $3.21 reported in 2020.
Sales were up 129% year over year to $11.7 billion. The top line surpassed the Zacks Consensus Estimate of $11.6 billion.
2022 Guidance
International Flavors estimates sales to be around $12.3 billion to $12.7 billion in 2022. Adjusted EBITDA is expected between $2.5 billion and $2.6 billion. The adjusted EBITDA margin is projected to grow 4-8% on a currency-neutral basis. Currency-neutral sales growth for the year is expected to be around 6% to 9%. However, foreign currency translation is likely to affect sales growth by 2 percentage points (PP) and adjusted operating EBITDA growth by 4 PP.
Price Performance
In the past year, International Flavors’ shares have lost 0.9% compared with the industry’s decline of 30.1%.
Image Source: Zacks Investment Research
Zacks Rank & Key Picks
International Flavors currently carries a Zacks Rank #4 (Sell).
Helen has an expected earnings growth rate of 0.6% for fiscal 2022. The Zacks Consensus Estimate for HELE’s fiscal 2022 earnings has been revised 3.7% upward in the past 60 days and is currently pinned at $11.72.
Helen’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 19.1%. HELE has a long-term earnings growth rate of 8%.
Medifast has an expected earnings growth rate of 18.6% for the current year. The Zacks Consensus Estimate for MED’s 2022 earnings has been revised 0.06%% upward in the past 60 days and is currently pegged at $16.19.
Medifast’s bottom line beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 17.3%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
International Flavors' (IFF) Q4 Earnings & Sales Beat Estimates
International Flavors & Fragrances Inc. (IFF - Free Report) reported adjusted earnings of $1.10 per share in fourth-quarter 2021, beating the Zacks Consensus Estimate of $1.04. The bottom line declined 17% from the year-ago quarter’s levels.
Including one-time items, the company reported earnings per share (EPS) of 35 cents compared with the prior-year quarter’s 57 cents.
International Flavors’ net sales came in at $3,031 million in the December-end quarter, surging 139% year over year. This was driven by the additional sales related to the merger with DuPont de Nemours, Inc.’s (DD - Free Report) Nutrition & Biosciences (N&B) business. The top line surpassed the Zacks Consensus Estimate of $2,960 million. During the October - December quarter, currency-neutral sales were up 10%, aided by a double-digit increase in Health & Biosciences and high-single-digit growth in Nourish, Pharma Solutions & Scent.
Operational Highlights
During the reported quarter, International Flavors’ adjusted cost of goods sold was significantly up 170% year over year to $2,044 million. Adjusted gross profit climbed 92% year over year to $987 million. Adjusted gross margin came in at 32.6% compared with 40.5% in the year-ago quarter.
Research and development expenses flared up 64% year over year to $166 million. Adjusted selling and administrative expenses shot up 92% year on year to $403 million during the fourth quarter. Adjusted operating EBITDA came in at $529 million, up 123% from the prior-year quarter’s $237 million due to the incremental profit related to the merger with N&B. Adjusted operating EBITDA margin was 17.4% compared with the year-earlier quarter’s 18.7%.
International Flavors & Fragrances Inc. Price and Consensus
International Flavors & Fragrances Inc. price-consensus-chart | International Flavors & Fragrances Inc. Quote
Segmental Performances
Revenues in the Nourish segment soared 128% year over year to $1,626 million during the December-end quarter. Adjusted operating EBITDA was $251 million, reflecting year-over-year growth of 88.7%.
Revenues generated in the Health & Bioscience segment came in at $646 million compared with the year-earlier quarter’s $35 million. Adjusted operating EBITDA was $156 million in the quarter compared with $11 million in the prior-year quarter.
Scent segment revenues came in at $555 million compared with the year-ago quarter’s $523 million. Adjusted operating EBITDA declined 5.4% year over year to $88 million.
Revenues in Pharma Solutions were $204 million in the fourth quarter. Adjusted operating EBITDA was $34 million.
Financial Position
International Flavors had cash and cash equivalents of $715 million at the end of 2021, up from the $657 million witnessed at the end of 2020. Long-term debt increased to $10.8 billion in 2021, from $3.8 billion in 2020.
International Flavors generated $1,437 million of cash from operating activities in 2021, compared with the prior-year’s $714 million. Capital invested in purchasing property, plant and equipment totaled $393 million in 2021 compared with $192 million in 2020. Dividend paid summed $667 million in 2021.
2021 Performance
International Flavors reported an adjusted EPS of $5.63 in 2021 compared with $5.70 reported in the prior year. Earnings beat the Zacks Consensus Estimate of $5.60. Including one-time items, the bottom line came in at $1.10, down 65.7% from $3.21 reported in 2020.
Sales were up 129% year over year to $11.7 billion. The top line surpassed the Zacks Consensus Estimate of $11.6 billion.
2022 Guidance
International Flavors estimates sales to be around $12.3 billion to $12.7 billion in 2022. Adjusted EBITDA is expected between $2.5 billion and $2.6 billion. The adjusted EBITDA margin is projected to grow 4-8% on a currency-neutral basis. Currency-neutral sales growth for the year is expected to be around 6% to 9%. However, foreign currency translation is likely to affect sales growth by 2 percentage points (PP) and adjusted operating EBITDA growth by 4 PP.
Price Performance
In the past year, International Flavors’ shares have lost 0.9% compared with the industry’s decline of 30.1%.
Zacks Rank & Key Picks
International Flavors currently carries a Zacks Rank #4 (Sell).
Some better-ranked stocks in the Consumer Staples sector include Helen of Troy (HELE - Free Report) and Medifast, Inc. (MED - Free Report) . While HELE sports a Zacks Rank #1 (Strong Buy), MED carries a Zacks Rank #2 (Buy), at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Helen has an expected earnings growth rate of 0.6% for fiscal 2022. The Zacks Consensus Estimate for HELE’s fiscal 2022 earnings has been revised 3.7% upward in the past 60 days and is currently pinned at $11.72.
Helen’s earnings beat the Zacks Consensus Estimate in each of the trailing four quarters, the average being 19.1%. HELE has a long-term earnings growth rate of 8%.
Medifast has an expected earnings growth rate of 18.6% for the current year. The Zacks Consensus Estimate for MED’s 2022 earnings has been revised 0.06%% upward in the past 60 days and is currently pegged at $16.19.
Medifast’s bottom line beat the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 17.3%.